Pfizer Inc., Gilead Sciences, Inc. and Teva Pharmaceutical Industries Ltd. are Dominating in the Global Small Molecule Sterile Injectable Drugs Market in 2020

Global Small Molecule Sterile Injectable Drugs Market is expected to grow with the CAGR of 7.2% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-small-molecule-sterile-injectable-drug-market

Global small molecule sterile injectable drugs market is a highly consolidated market, which includes specific number of key players as well as local players. The high demand for small molecule sterile injectable drugs increases due to high prevalence of chronic disease is putting pressure on the key players to bridge the gap and meet this high demand while maintaining patient care quality.

The major players dealing in global small molecule sterile injectable drugs market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio. For instance, in October 2020, Gilead Sciences, Inc. announced that it has signed an agreement with European Commission to provide access to Veklury in the European region. Under this, EU will procure this drug for six months from the company. This has increased the sale of drugs in EU region and contributed to the net revenue of the company.

Pfizer Inc. is the dominating player in global small molecule sterile injectable drugs market. The other key players existing in the small molecule sterile injectable drugs market includes Gilead Sciences, Inc., BIOCRYST PHARMACEUTICALS, INC., AstraZeneca, Genentech, Inc. (a subsidiary of F. Hoffmann-La Roche Ltd.), Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Hikma Pharmaceuticals PLC, AbbVie Inc., American Regent, Inc. (a Daiichii Sankyo Group Company), Amgen Inc., Bristol- Myers Squibb Company, Teligent, Eisai Co., Ltd., Teva Pharmaceutical Industries Ltd., Neuren Pharmaceuticals, Noxopharm, Amomed Pharma GmbH, Sanofi, Exelixis, Inc., Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA) among others.

Pfizer Inc.

Pfizer Inc. is headquartered in New York, U.S. and was founded in 1849. The company is exclusively concentrating on medicines that are used in hospitals to serving the customers and developing the relationships. Furthermore company is primarily focusing on R&D of oncology, vaccines, rare diseases, internal medicine and hospital segment. The company has wide range of products under categories such as accupril, adenosine, aldactazide, acetylcysteine solution, usp, adenosine, amidate (etomidate injection, usp), celebrex, diflucan, lyrica, ibrance, norvasc, chantix, lipitor, eliquis and many others among which acetylcysteine solution, USP, adenosine and amidate (etomidate injection, USP) are the market focused categories.

The company has wide global presence across the world in Americas, Europe, Asia-Pacific and Middle East and Africa with its various subsidiaries such as Therachon Holding AG (Switzerland) Medivation, Inc. (U.S.), Anacor Pharmaceuticals (U.S.), Warner-Lambert (New Jersey), Pharmacia (U.S.) and others.

Gilead Sciences, Inc.

Gilead Sciences, Inc. is headquartered in California, U.S. and was founded in 1987. The company is focused on delivering innovative therapeutics for people suffering with life-threating diseases. The company has wide range of products under categories such as medicine, pipeline, clinical trials and research among which medicine and pipeline are the market focused categories.

For instance,

  • In April 2021, Gilead Sciences announced that it will expand the availability of Remdesivir in India by donating 40,000 vials of Veklury. This will increase the presence of the company in such a large market and will contribute in business expansion in the forecast period to India.

The company has wide global presence across the world in Americas, Europe, Asia-Pacific and Middle East and Africa with its various subsidiaries such as Gilead Biopharmaceutical UC (Ireland), Gilead Science Limited (Israel), Gilead Sciences S.r.l (Italy), Gilead Science KK (Japan), Kp EU C.V. (Netherlands) among others.

Teva Pharmaceutical Industries Ltd.

Teva Pharmaceuticals Industries Ltd. is headquartered in Parsippany, U.S. and was founded in 1901. The company is exclusively focusing on respiratory and movement disorders. The company has wide range of products under categories such as actiq (fentanyl citrate) oral transmucosal lozenge, airduo respiclick (fluticasone propionate and salmeterol) inhalation powder, austedo (deutetrabenazine) tablets, azilect (rasagiline) tablets, adenosine injection, USP, alprostadil, amikacin, bleomycin, carboplatin, cisatracurium besylate injection, USP, cisplatin, dacarbazine, daunorubicin, doxorubicin and epinephrine injection, USP among which adenosine injection, USP, alprostadil, amikacin, bleomycin, carboplatin, cisatracurium besylate injection, USP, cisplatin, dacarbazine, daunorubicin, doxorubicin and epinephrine injection, USP are the market focused categories.

For instance,

  • In October 2020, Teva Pharmaceutical Industries Ltd. announced the expansion of its manufacturing unit in Lenexa, Kansas. Owing to rise in demand for sample testing kits during the COVID-19 pandemic, the company will be able to produce large number sample collection kits in the region. This will drive the growth of the market in fore coming years.

The company has wide global presence across the world in Americas, Europe, Asia-Pacific and Middle East and Africa with its various subsidiaries such as Actavis Group PTC ehf (Iceland), Actavis Pharma Holding ehf (Iceland), IVAX UK Limited (U.K.), Mepha Schweiz AG (Switzerland), Merckle GmbH (Germany) and others.